We are live on ! Find out more
TRAW icon

Traws Pharma

29 hedge funds and large institutions have $5.87M invested in Traws Pharma in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

381% more capital inflows, than outflows

Capital inflows: $2.46M | Capital outflows: $512K

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

38% more funds holding

Funds holding: 21 → 29 (+8)

2.68% more ownership

Funds ownership: 3.47% → 6.15% (+2.7%)

Holders
29
Holders Change
+8
Holders Change %
+38.1%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
6
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TRAW Hedge Fund Activity: Q2 2020 in Review

29 of the 4,891 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2020, worth a combined $5.87M — up 234% from $1.76M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TRAW positions and 4 closed out — a net gain of 9 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.55M. The largest seller was Susquehanna International Group, cutting an estimated $441K.

  • 29 institutional investors held Traws Pharma (TRAW) as of Q2 2020, up from 21 in Q1 2020.
  • Funds reported $5.87M of Traws Pharma stock for Q2 2020, up 234% quarter-over-quarter.
  • 13 funds opened new Traws Pharma positions in Q2 2020 and 4 closed out, a net change of +9 holders.
  • The largest Traws Pharma buyer in Q2 2020 was Vanguard Group, an estimated $1.55M added.
  • The largest Traws Pharma seller in Q2 2020 was Susquehanna International Group, an estimated $441K sold.

Based on aggregated 13F filings for Q2 2020.